Diagens Annual Results: Medical AI Landscape Transformation

Diagens Biotech, a leader in medical imaging AI, reported significant growth in its first annual results post-IPO, with a revenue of RMB 164 million and a 133.7% year-on-year increase. The company’s iMedImage® foundation model, featuring 104 billion parameters, has become the primary growth engine, significantly improving the efficiency of developing specialized medical AI models. With partnerships extending to over 400 medical institutions, Diagens seeks to scale its technology globally, aiming to bridge gaps in healthcare resources.